• Home
  • Motorcycles
  • Electric Motorcycles
  • 3 wheelers
  • FUV Electric 3 wheeler
  • Shop
  • Listings

Subscribe to Updates

Get the latest creative news from CycleNews about two, three wheelers and Electric vehicles.

What's Hot

A Neuralink Rival Just Tested a Brain Implant in a Person

MSI Titan 18 HX AI Review: The Ultimate Gaming Laptop

Cortech Versa-Flo Jacket Review

Facebook Twitter Instagram
  • Home
  • Motorcycles
  • Electric Motorcycles
  • 3 wheelers
  • FUV Electric 3 wheeler
  • Shop
  • Listings
Facebook Twitter Instagram Pinterest
Cycle News
Submit Your Ad
Cycle News
You are at:Home » Wegovy Can Keep Weight Off for at Least 4 Years, Research Shows
Electric Motorcycles

Wegovy Can Keep Weight Off for at Least 4 Years, Research Shows

cycleBy cycleMay 16, 202403 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


A large, long-term trial of the weight-loss medication Wegovy (semaglutide) found that people tended to lose weight over the first 65 weeks on the drug—about one year and three months—but then hit a plateau or “set point.” But that early weight loss was generally maintained for up to four years while people continued taking the weekly injections.

The findings, published Monday in Nature Medicine, come from a fresh analysis of data from the SELECT trial, which was designed to look at the drug’s effects on cardiovascular health. The trial—a multicenter, double-blind, randomized, placebo-controlled trial—specifically enrolled people with existing cardiovascular disease who also were overweight or obese but did not have diabetes. In all, the trial included 17,604 people from 41 countries. Seventy-two percent of them were male, 84 percent were white, and the average age was about 62 years old.

Last year, researchers published the trial’s primary results, which showed that semaglutide reduced participants’ risk of heart attack, stroke, and cardiovascular-related deaths by 20 percent over the span of a little over three years.

In the new analysis with yet longer follow-up of the same participants, researchers focused on their weight-loss trajectories and endpoints. People taking semaglutide saw their weight decline steadily over the first 65 weeks of treatment, then plateau. However, the initial weight loss was sustained through 208 weeks (four years) of follow-up. On average, people taking the drug lost 10.2 percent of their weight, while the placebo group lost just 1.5 percent. That amounts to an 8.7 percent treatment difference.

That weight loss is less than what has been seen in other trials of semaglutide. In 2021, researchers published a study in The New England Journal of Medicine showing people on the drug lost 14.9 percent of their weight, while those on a placebo lost 2.4 percent—a treatment difference of 12.5 percent.

Researchers behind the SELECT trial, which was funded by Wegovy’s maker, Novo Nordisk, speculate that the trials’ different designs may explain the difference in weight loss. The earlier trial was designed to study weight loss in people who were specifically trying to lose weight and who also tended to be younger than those in the SELECT trial. In addition to semaglutide treatment, the older trial included other lifestyle interventions to aid in weight loss. The SELECT trial participants, on the other hand, weren’t specifically seeking to lose weight and didn’t get any additional lifestyle interventions for weight loss.

Still, researchers saw clinically meaningful weight loss across both sexes and all body sizes and geographic regions. Of the people who received semaglutide, 52.4 percent moved into a lower category of body mass index during the trial, compared with just 15.7 percent of the placebo group. And in the semaglutide group, the proportion of people with obesity fell from 71 percent to 43.3 percent, while the placebo group saw the proportion drop from 71.9 percent to 67.9 percent.

The study has limitations, most notably that it mostly enrolled older white males. Thus, the weight-loss findings may not be generalizable. However, the authors conclude that the study supports broad use of semaglutide in people with cardiovascular disease who also are overweight or have obesity. The looming question researchers next have to face is just how long people will need to stay on the effective but currently pricey drug.

This story originally appeared on Ars Technica.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleTop 10 Things to Know
Next Article The 11 Best Early Memorial Day 2024 Mattress Deals
cycle
  • Website

Related Posts

A Neuralink Rival Just Tested a Brain Implant in a Person

June 2, 2025

MSI Titan 18 HX AI Review: The Ultimate Gaming Laptop

June 2, 2025

Cortech Versa-Flo Jacket Review

June 2, 2025
Add A Comment

Leave A Reply Cancel Reply

You must be logged in to post a comment.

Demo
Top Posts

A Neuralink Rival Just Tested a Brain Implant in a Person

June 2, 2025

The urban electric commuter FUELL Fllow designed by Erik Buell is now opening orders | thepack.news | THE PACK

July 29, 2023

2024 Yamaha Ténéré 700 First Look [6 Fast Facts For ADV Riding]

July 29, 2023
Stay In Touch
  • Facebook
  • YouTube
  • TikTok
  • WhatsApp
  • Twitter
  • Instagram
Latest Reviews

Subscribe to Updates

Get the latest tech news from FooBar about tech, design and biz.

Demo
Most Popular

A Neuralink Rival Just Tested a Brain Implant in a Person

June 2, 2025

The urban electric commuter FUELL Fllow designed by Erik Buell is now opening orders | thepack.news | THE PACK

July 29, 2023

2024 Yamaha Ténéré 700 First Look [6 Fast Facts For ADV Riding]

July 29, 2023
Our Picks

Can Reddit—the Internet’s Greatest Authenticity Machine—Survive Its Own IPO?

Lenovo ThinkBook Plus (Gen 5) Review: A Windows and Android Hybrid

Shortcut to motorcycle license? How about this electric motorcycle course?

Subscribe to Updates

Get the latest news from CycleNews about two, three wheelers and Electric vehicles.

© 2025 cyclenews.blog
  • Home
  • About us
  • Get In Touch
  • Shop
  • Listings
  • My Account
  • Submit Your Ad
  • Terms & Conditions
  • Stock Ticker

Type above and press Enter to search. Press Esc to cancel.